Merck & Co shares climbed nearly 1% in US trading following the release of its second-quarter financial results.
The US pharmaceutical company also raised its full-year revenue forecast, signaling confidence in its growth trajectory despite a competitive oncology landscape.
Keytruda continues to be the primary engine of Merck’s revenue growth, with recent reports indicating the drug generated $8.
The upward revision to the annual outlook was primarily driven by stronger-than-expected sales of Keytruda, the company’s flagship cancer treatment.
Keytruda continues to be the primary engine of Merck’s revenue growth, with recent reports indicating the drug generated $8.3 billion in sales during the latest period. The sustained demand for the immunotherapy drug has allowed Merck to outpace market expectations and reinforce its position in the oncology sector.
Investors have closely watched Merck’s ability to maintain Keytruda’s momentum as patent cliffs and new competitors emerge.
The raised forecast suggests that the drug’s expansion into new indications and markets is proceeding ahead of schedule.